Famotidine


Description

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Read more

Pharmacology

Indication

For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).

Pharmacodynamic

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointest... Read more

Mechanism of action

Famotidine binds competitively to H2-receptors located on the basolateral membrane of the... Read more

Absorption

The bioavailability of oral doses is 40-45%.

Protein binding

15-20%

Volume of distribution

Information currently not available.

Clearance

renal cl=250-450 mL/min

Half life

2.5-3.5 hours

Route of elimination

Renal clearance is 250-450 mL/min, indicating some tubular excretion.

Toxicity

Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptom... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Agitation US
  • infant
  • Kind: experimental
    • Percent: 14%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 4.7%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 1.7%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 1.3%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 1.2%
  • Clinical Trial
    Convulsions US
    Clinical Trial Post Marketing
    Impotence US
    Clinical Trial Post Marketing
    Gynecomastia US
    Clinical Trial Post Marketing
    Tinnitus US
    Clinical Trial Post Marketing
    Taste Disorder US
    Clinical Trial Post Marketing
    Grand mal seizure US
    Clinical Trial Post Marketing
    Psychic disturbances US
    Clinical Trial Post Marketing
    Muscle Cramps US
    Clinical Trial Post Marketing
    Arthralgia US
    Clinical Trial Post Marketing
    Conjunctival injection US
    Clinical Trial Post Marketing
    Musculoskeletal Pain US
    Clinical Trial Post Marketing
    Urticaria US
    Clinical Trial Post Marketing
    Rash US
    Clinical Trial Post Marketing
    Dry Skin US
    Clinical Trial Post Marketing
    Flushing US
    Clinical Trial Post Marketing
    Acne US
    Clinical Trial Post Marketing
    Pruritus US
    Clinical Trial Post Marketing
    Stevens Johnson syndrome (very rare) US
    Clinical Trial Post Marketing
    Alopecia US
    Clinical Trial Post Marketing
    Bronchospasm US
    Clinical Trial Post Marketing
    Interstitial Pneumonia US
    Clinical Trial Post Marketing
    Anorexia US
    Clinical Trial Post Marketing
    Abdominal Discomfort US
    Clinical Trial Post Marketing
    Nausea US
    Clinical Trial Post Marketing
    Vomiting US
    Clinical Trial Post Marketing
    Liver enzyme abnormalities US
    Clinical Trial Post Marketing
    Cholestatic jaundice US
    Clinical Trial Post Marketing
    Palpitation US
    Clinical Trial Post Marketing
    AV Block US
    Clinical Trial Post Marketing
    Orbital or facial edema US
    Clinical Trial Post Marketing
    Angioedema US
    Clinical Trial Post Marketing
    Anaphylaxis US
    Clinical Trial Post Marketing
    Thrombocytopenia US
    Clinical Trial Post Marketing
    Leukopenia US
    Clinical Trial Post Marketing
    Pancytopenia US
    Clinical Trial Post Marketing
    Rare cases of agranulocytosis US
    Clinical Trial Post Marketing
    Dry Mouth US
    Clinical Trial Post Marketing
    Fever US
    Clinical Trial Post Marketing
    Asthenia US
    Clinical Trial Post Marketing
    Fatigue US
    Clinical Trial Post Marketing
    Arrhythmia US
    Clinical Trial Post Marketing

    Contraindications

    • Route:
      • Oral
      • Intravenous
    • Hypersensitivity:
      • H2-receptor antagonists
    • Regions: US

    Food Interactions

    • Avoid alcohol.
    • Limit caffeine intake.
    • Take without regard to meals, food may slightly increase the product's bioavailability.

    Interactions

    Type in a drug name to check for interaction with Famotidine

    2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Famotidine.
    2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Famotidine.
    4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.
    Famotidine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Abexinostat.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acebutolol.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aceprometazine.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acetyldigoxin.
    The excretion of Famotidine can be decreased when combined with Acetylsalicylic acid.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.
    The excretion of Famotidine can be decreased when combined with Acyclovir.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Adenosine.
    The serum concentration of Agmatine can be increased when it is combined with Famotidine.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ajmaline.
    Famotidine can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
    The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Famotidine.
    The risk or severity of QTc prolongation can be increased when Famotidine is combined with Alimemazine.
    The excretion of Allopurinol can be decreased when combined with Famotidine.
    The excretion of Alprostadil can be decreased when combined with Famotidine.
    The serum concentration of Amantadine can be increased when it is combined with Famotidine.

    References

      Information currently not available.

    Recent Questions